Related Experiment Videos

[The efficacy of indapamide in different cardiovascular outcome--meta-analysis]

Valentin Brodszky1, Viktor Nagy, Csaba Farsang

  • 1Budapesti Corvinus Egyetem Közszolgálati Tanszék, Egészségügyi-gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest. valentin.brodszky@uni-corvinus.hu

Orvosi Hetilap
|June 26, 2007
PubMed

Insights

Indapamide effectively lowers blood pressure and reduces stroke risk, with well-tolerated outcomes. This meta-analysis confirms its efficacy in cardiovascular health for patients requiring antihypertensive treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Context:

  • Thiazide diuretics are first-line antihypertensives.
  • Previous studies show thiazide efficacy, but a comprehensive indapamide analysis was lacking.

Purpose:

  • To conduct a meta-analysis of all randomized controlled trials involving indapamide.
  • To assess indapamide's efficacy in cardiovascular and safety outcomes.

Summary:

  • Meta-analysis of 9 trials (10,108 patients) showed indapamide prevents stroke (NNT=47.8).
  • Indapamide significantly reduced systolic and diastolic blood pressure compared to placebo (7.28/3.50 mmHg).
  • Indapamide reduced systolic blood pressure more than active controls (1.30 mmHg) and decreased left ventricular mass index more than enalapril.

Impact:

  • Indapamide is effective in stroke prevention and blood pressure reduction.
  • Indapamide demonstrates significant benefits in reducing left ventricular mass index.
  • Adverse drug reaction rates were similar between indapamide and placebo groups, indicating good tolerability.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...